Synthesis and serotonin transporter activity of sulphur-substituted α-alkyl phenethylamines as a new class of anticancer agents

European Journal of Medicinal Chemistry

Volumn 44, Issue 12, 2009, Pages 4862-4888

  Cloonan, Suzanne M ^a   Keating, John J ^a   Butler, Stephen G ^a   Knox, Andrew J S ^a   Jørgensen, Anne M ^b   Peters, Günther H ^b   Rai, Dilip ^c   Corrigan, Desmond ^a   Lloyd, David G ^a   Williams, D Clive ^a   Meegan, Mary J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Alkylphenethylamine; 4 MTA; Antiproliferative activity; Apoptosis; SERT

Indexed keywords

1 (4 METHYLSULFANYL PHENYL) PROPYLAMINE; 1 METHYL 2 (4 PHENYLSULFANYL PHENYL) ETHYLAMINE; ALKYL GROUP; ANTINEOPLASTIC AGENT; METHYL GROUP; SEROTONIN TRANSPORTER; SULPHUR SUBSTITUTED ALPHA ALKYL PHENETHYLAMINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; MOLECULAR MODEL;

AMPHETAMINES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHENETHYLAMINES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFUR;

EID: 70449674733     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.07.027     Document Type: Article

References (89)

1. Schloss P., and Williams D.C. The serotonin transporter: a primary target for antidepressant drugs. J. Psychopharmacol. 12 (1998) 115-121
2. Ramamoorthy S., Bauman A.L., Moore K.R., Han H., Yang-Feng T., Chang A.S., Ganapathy V., and Blakely R.D. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 2542-2546
3. Wade P.R., and Westfall J.A. Ultrastructure of enterochromaffin cells and associated neural and vascular elements in the mouse duodenum. Cell Tissue Res. 241 (1985) 557-563
4. Gershon M.D. Plasticity in serotonin control mechanisms in the gut. Curr. Opin. Pharmacol. 3 (2003) 600-607
5. Rudnick G. Active transport of 5-hydroxytryptamine by plasma membrane vesicles isolated from human blood platelets. J. Biol. Chem. 252 (1977) 2170-2174
6. Meredith E.J., Holder M.J., Chamba A., Challa A., Drake Lee A., Bunce C.M., Drayson M.T., Pilkington G., Blakely R.D., Dyer M.J.S., Barnes N.M., and Gordon J. The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential antitumor target for psychotropics. FASEB J. 19 (2005) 1187-1189
7. Serafeim A., Grafton G., Chamba A., Gregory C.D., Blakely R.D., Bowery N.G., Barnes N.M., and Gordon J. 5-Hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors. Blood 99 (2002) 2545-2553
8. Serafeim A., Holder M.J., Grafton G., Chamba A., Drayson M.T., Luong Q.T., Bunce C.M., Gregory C.D., Barnes N.M., and Gordon J. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101 (2003) 3212-3219
9. Simantov R., and Tauber M. The abused drug MDMA (Ecstasy) induces programmed death of human serotonergic cells. FASEB J. 11 (1997) 141-146
10. Bengel D., Isaacs K.R., Heils A., Lesch K.P., and Murphy D.L. The appetite suppressant d-fenfluramine induces apoptosis in human serotonergic cells. Neuroreport 9 (1998) 2989-2993
11. Reddy K.K., Lefkove B., Chen L.B., Govindarajan B., Carracedo A., Velasco G., Carrillo C.O., Bhandarkar S.S., Owens M.J., Mechta-Grigoriou F., and Arbiser J.L. The antidepressant sertraline downregulates Akt and has activity against melanoma cells. Pigment Cell Melanoma Res. 21 (2008) 451-456
12. Xia Z., Bergstrand A., DePierre J.W., and Nassberger L. The antidepressants imipramine, clomipramine, and citalopram induce apoptosis in human acute myeloid leukemia HL-60 cells via caspase-3 activation. J. Biochem. Mol. Toxicol. 13 (1999) 338-347
13. Koch J.M., Kell S., and Aldenhoff J.B. Differential effects of fluoxetine and imipramine on the phosphorylation of the transcription factor CREB and cell-viability. J. Psychiatr. Res. 37 (2003) 53-59
14. Levkovitz Y., Gil-Ad I., Zeldich E., Dayag M., and Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J. Mol. Neurosci. 27 (2005) 29-42
15. Arimochi H., and Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur. J. Pharmacol. 541 (2006) 17-23
16. Xia Z., DePierre J.W., and Nassberger L. Modulation of apoptosis induced by tricyclic antidepressants in human peripheral lymphocytes. J. Biochem. Mol. Toxicol. 12 (1998) 115-123
17. Karlsson H., Gu Y., DePierre J., and Nassberger L. Induction of apoptosis in proliferating lymphocytes by tricyclic antidepressants. Apoptosis 3 (1998) 255-260
18. Schuster C., Fernbach N., Rix U., Superti-Furga G., Holy M., Freissmuth M., Sitte H.H., and Sexl V. Selective serotonin reuptake inhibitors - a new modality for the treatment of lymphoma/leukaemia?. Biochem. Pharmacol. (2007)
19. Hayat S., Williams R.J., and Rattray M. Serotonin transporter expression is not sufficient to confer cytotoxicity to 3,4-methylenedioxymethamphetamine (MDMA) in vitro. J. Psychopharmacol. 20 (2006) 257-263
20. Garcia-Colunga J., Awad J.N., and Miledi R. Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2041-2044
21. Gaidano G., and Carbone A. AIDS-related lymphomas: from pathogenesis to pathology. Br. J. Haematol. 90 (1995) 235-243
22. Harris N.L., and Horning S.J. Burkitt's lymphoma - the message from microarrays. N. Engl. J. Med. 354 (2006) 2495-2498
23. Burkitt D., and O'Conor G.T. Malignant lymphoma in African children. I. A clinical syndrome. Cancer 14 (1961) 258-269
24. WHO Expert Committee on Drug Dependence. Thirty-second Report. World Health Organ. Tech. Rep. Ser. 903, 2001, pp. 1-26.
25. Huang X., Marona-Lewicka D., and Nichols D.E. p-Methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur. J. Pharmacol. 229 (1992) 31-38
26. Murphy J., Flynn J.J., Cannon D.M., Guiry P.J., McCormack P., Baird A.W., McBean G.J., and Keenan A.K. In vitro neuronal and vascular responses to 5-hydroxytryptamine: modulation by 4-methylthioamphetamine, 4-methylthiomethamphetamine and 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 444 (2002) 61-67
27. Hurtado-Guzman C., Fierro A., Iturriaga-Vasquez P., Sepulveda-Boza S., Cassels B.K., and Reyes-Parada M. Monoamine oxidase inhibitory properties of optical isomers and N-substituted derivatives of 4-methylthioamphetamine. J. Enzyme Inhib. Med. Chem. 18 (2003) 339-347
28. Jorgensen A.M., Tagmose L., Jorgensen A.M., Topiol S., Sabio M., Gundertofte K., Bogeso K.P., and Peters G.H. Homology modeling of the serotonin transporter: insights into the primary escitalopram-binding Site. ChemMedChem 2 (2007) 815-826
29. Holland G.F., Buck C.J., and Weissman A. Anorexigenic agents: aromatic substituted 1-phenyl-2-propylamines. J. Med. Chem. 6 (1963) 519-524
30. Gallardo-Godoy A., Fierro A., McLean T.H., Castillo M., Cassels B.K., Reyes-Parada M., and Nichols D.E. Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. J. Med. Chem. 48 (2005) 2407-2419
31. Kirkbride K.P., Ward A.D., Jenkins N.F., Klass G., and Coumbaros J.C. Synthesis of 4-methyl-5-arylpyrimidines and 4-arylpyrimidines: route specific markers for the Leuckardt preparation of amphetamine, 4-methoxyamphetamine, and 4-methylthioamphetamine. Forensic Sci. Int. 115 (2001) 53-67
32. Jacob III P., Anderson III G., Meshul C.K., Shulgin A.T., and Castagnoli Jr. N. Monomethylthio analogues of 1-(2,4,5-trimethoxyphenyl)-2-aminopropane. J. Med. Chem. 20 (1977) 1235-1239
33. Shulgin S.A., and Shulgin A. PIHKAL: A Chemical Love Story (1992), Transform Press,, Berkeley, CA
34. Rezende C.R., Nunez C., Sepulveda-Boza S., Cassels B.K., and Hurtado-Guzman C. S-oxidation products of alkylthioamphetamines. Synth. Commun. 32 (2002) 2741-2750
35. Tanaka A., Terasawa T., Hagihara H., Sakuma Y., Ishibe N., Sawada M., Takasugi H., and Tanaka H. Inhibitors of acyl-CoA: cholesterol O-acyltransferase (ACAT). Part 1: identification and structure-activity relationships of a novel series of substituted N-alkyl-N-biphenylylmethyl-N′-arylureas. Bioorg. Med. Chem. 6 (1998) 15-30
36. Cabiddu M.G., Cabiddu S., Cadoni E., Corrias R., Fattuoni C., Floris C., and Melis S. Metallation reactions. 22. Regioselective metallation of (trifluoromethyl)(alkylthio) benzenes. J. Organomet. Chem. 531 (1997) 125-140
37. Cabiddu S., Fattuoni C., Floris C., Gelli G., Melis S., and Sotgiu F. Metalation reactions. 14. Regiospecific preparation of polysubstituted benzenes via mono-lithiation or di-lithiation reactions of aromatic thioethers. Tetrahedron 46 (1990) 861-884
38. Sulzer D., Sonders M.S., Poulsen N.W., and Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog. Neurobiol. 75 (2005) 406-433
39. Schonn J.-S., Desnos C., Henry J.-P., and Darchen F. Transmitter uptake and release in PC12 cells overexpressing plasma membrane monoamine transporters. J. Neurochem. 84 (2003) 669-677
40. Steele T.D., McCann U.D., and Ricaurte G.A. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. Addiction 89 (1994) 539-551
41. Verrico C.D., Miller G.M., and Madras B.K. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl.) (2005) 1-15
42. Rothman R.B., Jayanthi S., Wang X., Dersch C.M., Cadet J.L., Prisinzano T., Rice K.C., and Baumann M.H. High-dose fenfluramine administration decreases serotonin transporter binding, but not serotonin transporter protein levels, in rat forebrain. Synapse 50 (2003) 233-239
43. Callaghan P.D., Owens W.A., Javors M.A., Sanchez T.A., Jones D.J., Irvine R.J., and Daws L.C. In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function. J. Neurochem. 100 (2007) 617-627
44. 3H]serotonin from rat brain synaptosomes. J. Med. Chem. 25 (1982) 530-535
45. Roman D.L., Saldana S.N., Nichols D.E., Carroll F.I., and Barker E.L. Distinct molecular recognition of psychostimulants by human and Drosophila serotonin transporters. J. Pharmacol. Exp. Ther. 308 (2004) 679-687
46. Lesch K.P., Wolozin B.L., Murphy D.L., and Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J. Neurochem. 60 (1993) 2319-2322
47. McCammon J.A. Theory of biomolecular recognition. Curr. Opin. Struct. Biol. 8 (1998) 245-249
48. Claussen H., Buning C., Rarey M., and Lengauer T. FlexE: efficient molecular docking considering protein structure variations. J. Mol. Biol. 308 (2001) 377-395
49. Walline C.C., Nichols D.E., Carroll F.I., and Barker E.L. Comparative molecular field analysis using selectivity fields reveals residues in the third transmembrane helix of the serotonin transporter associated with substrate and antagonist recognition. J. Pharmacol. Exp. Ther. 325 (2008) 791-800
50. Henry L.K., Field J.R., Adkins E.M., Parnas M.L., Vaughan R.A., Zou M.F., Newman A.H., and Blakely R.D. Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J. Biol. Chem. 281 (2006) 2012-2023
51. Chen J.G., Sachpatzidis A., and Rudnick G. The third transmembrane domain of the serotonin transporter contains residues associated with substrate and cocaine binding. J. Biol. Chem. 272 (1997) 28321-28327
52. Andersen J., Taboureau O., Hansen K.B., Olsen L., Egebjerg J., Stromgaard K., and Kristensen A.S. Location of the antidepressant binding site in the serotonin transporter: importance of Ser-438 in recognition of citalopram and tricyclic antidepressants. J. Biol. Chem. 284 (2009) 10276-10284
53. Hurtado-Guzman C., Martinez-Alvarado P., Dagnino-Subiabre A., Paris I., Caviedes P., Caviedes R., Cassels B.K., and Segura-Aguilar J. Neurotoxicity of some MAO inhibitors in adult rat hypothalamic cell culture. Neurotox. Res. 4 (2002) 161-163
54. Carmo H., Brulport M., Hermes M., Oesch F., de Boer D., Remiao F., Carvalho F., Schon M.R., Krebsfaenger N., Doehmer J., Bastos Mde L., and Hengstler J.G. CYP2D6 increases toxicity of the designer drug 4-methylthioamphetamine (4-MTA). Toxicology 229 (2007) 236-244
55. Capela J.P., Ruscher K., Lautenschlager M., Freyer D., Dirnagl U., Gaio A.R., Bastos M.L., Meisel A., and Carvalho F. Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor-dependent and potentiated under hyperthermia. Neuroscience 139 (2006) 1069-1081
56. Capela J.P., Meisel A., Abreu A.R., Branco P.S., Ferreira L.M., Lobo A.M., Remiao F., Bastos M.L., and Carvalho F. Neurotoxicity of Ecstasy metabolites in rat cortical neurons, and influence of hyperthermia. J. Pharmacol. Exp. Ther. 316 (2006) 53-61
57. Carvalho M., Hawksworth G., Milhazes N., Borges F., Monks T.J., Fernandes E., Carvalho F., and Bastos M.L. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch. Toxicol. 76 (2002) 581-588
58. Milhazes N., Cunha-Oliveira T., Martins P., Garrido J., Oliveira C., Rego A.C., and Borges F. Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine ("ecstasy") and its metabolites on undifferentiated PC12 cells: a putative structure-toxicity relationship. Chem. Res. Toxicol. 19 (2006) 1294-1304
59. Carvalho M., Milhazes N., Remiao F., Borges F., Fernandes E., Amado F., Monks T.J., Carvalho F., and Bastos M.L. Hepatotoxicity of 3,4-methylenedioxyamphetamine and alpha-methyldopamine in isolated rat hepatocytes: formation of glutathione conjugates. Arch. Toxicol. 78 (2004) 16-24
60. Carmo H., de Boer D., Remiao F., Carvalho F., dos Reys L.A., and Bastos Mde L. Identification of 4-methylthioamphetamine and some of its metabolites in mouse urine by GC-MS after acute administration. J. Anal. Toxicol. 26 (2002) 228-232
61. Carmo H., Hengstler J.G., de Boer D., Ringel M., Carvalho F., Fernandes E., Remiao F., dos Reys L.A., Oesch F., and de Lourdes Bastos M. Comparative metabolism of the designer drug 4-methylthioamphetamine by hepatocytes from man, monkey, dog, rabbit, rat and mouse. Naunyn Schmiedebergs Arch. Pharmacol. 369 (2004) 198-205
62. Ben-Bassat H., Goldblum N., Mitrani S., Goldblum T., Yoffey J.M., Cohen M.M., Bentwich Z., Ramot B., Klein E., and Klein G. Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int. J. Cancer 19 (1977) 27-33
63. Biedler J.L., Roffler-Tarlov S., Schachner M., and Freedman L.S. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 38 (1978) 3751-3757
64. Lode H.N., Bruchelt G., Seitz G., Gebhardt S., Gekeler V., Niethammer D., and Beck J. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression. Eur. J. Cancer 31A (1995) 586-590
65. ter Haar E., Kowalski R.J., Hamel E., Lin C.M., Longley R.E., Gunasekera S.P., Rosenkranz H.S., and Day B.W. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 35 (1996) 243-250
66. Lin C.-K.E., Nguyen T.T., Morgan T.L., Mei R.-L., Kaptein J.S., Kalunta C.I., Yen C.F., Park E., Zou H.Y., and Lad P.M. Apoptosis may be either suppressed or enhanced with strategic combinations of antineoplastic drugs or anti-IgM. Exp. Cell Res. 244 (1998) 1-13
67. Nusbaum N.J., and Abraham T. Paclitaxel effect on a leukemia cell line: importance of paclitaxel concentration. Anticancer Drugs 6 (1995) 427-431
68. Holder M.J., Barnes N.M., Gregory C.D., and Gordon J. Lymphoma cells protected from apoptosis by dysregulated bcl-2 continue to bind annexin V in response to B-cell receptor engagement: a cautionary tale. Leuk. Res. 30 (2006) 77-80
69. Pae H.O., Yoo J.C., Choi B.M., Kang C.L., Kim J.D., and Chung H.T. Apoptotic cell death induced by taxol is inhibited by nitric oxide in human leukemia HL-60 cells. Immunopharmacol. Immunotoxicol. 21 (1999) 667-682
70. Motl S., Zhuang Y., Waters C.M., and Stewart C.F. Pharmacokinetic considerations in the treatment of CNS tumours. Clin. Pharmacokinet. 45 (2006) 871-903
71. King L.A., and Van-Der Meer A.J.P. New synthetic drugs in the European Union. Science & Justice 41 (2001) 200-202
72. De Letter E.A., Coopman V.A., Cordonnier J.A., and Piette M.H. One fatal and seven non-fatal cases of 4-methylthioamphetamine (4-MTA) intoxication: clinico-pathological findings. Int. J. Legal Med. 114 (2001) 352-356
73. Poortman A.J., and Lock E. Analytical profile of 4-methylthioamphetamine (4-MTA), a new street drug. Forensic Sci. Int. 100 (1999) 221-233
74. Decaestecker T., De Letter E., Clauwaert K., Bouche M.P., Lambert W., Van Bocxlaer J., Piette M., Van den Eeckhout E., Van Peteghem C., and De Leenheer A. Fatal 4-MTA intoxication: development of a liquid chromatographic-tandem mass spectrometric assay for multiple matrices. J. Anal. Toxicol. 25 (2001) 705-710
75. Elliott S.P. Fatal poisoning with a new phenylethylamine: 4-methylthioamphetamine (4-MTA). J. Anal. Toxicol. 24 (2000) 85-89
76. EMCDDA. Report on the Risk Assessment of 4-MTA in the Framework of the Joint Action on New Synthetic Drugs (1999), Office for Official Publications of the European Community, Luxembourg pp. 3-114
77. De Letter E.A., Piette M.H., Lambert W.E., and Cordonnier J.A. Amphetamines as potential inducers of fatalities: a review in the district of Ghent from 1976-2004. Med. Sci. Law 46 (2006) 37-65
78. Garcia-Repetto R., Moreno E., Soriano T., Jurado C., Gimenez M.P., and Menendez M. Tissue concentrations of MDMA and its metabolite MDA in three fatal cases of overdose. Forensic Sci. Int. 135 (2003) 110-114
79. M. Hanxian Huang, Ph.D., Burkitt Lymphoma, Emedicinecom, 2005.
80. Spina M., Tirelli U., Zagonel V., Gloghini A., Volpe R., Babare R., Abbruzzese L., Talamini R., Vaccher E., and Carbone A. Burkitt's lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75 patients. Cancer 82 (1998) 766-774
81. Grogg K.L., Miller R.F., and Dogan A. HIV infection and lymphoma. J. Clin. Pathol. 60 (2007) 1365-1372
82. Hurtado-Guzman C.I.-V., Patricio, Zapata-Torres G., and Cassels B.K. Geometrical isomerism in β-nitrostyrenes: preferred conformations of (E)- and (Z)-1-(4-methylthiophenyl)-2-nitrobutenes. J. Chilean Chem. Soc. 49 (2004) 257-260
83. J.J. Talley, Preparation of isoxazole compounds as cyclooxygenase inhibitors. US Patent 5859257 (GD Searle and Co, USA), 1999.
84. Tate C.G., Haase J., Baker C., Boorsma M., Magnani F., Vallis Y., and Williams D.C. Comparison of seven different heterologous protein expression systems for the production of the serotonin transporter. Biochim. Biophys. Acta 1610 (2003) 141-153
85. Baker M.P., Eliopoulos A.G., Young L.S., Armitage R.J., Gregory C.D., and Gordon J. Prolonged phenotypic, functional, and molecular change in group I Burkitt lymphoma cells on short-term exposure to CD40 ligand. Blood 92 (1998) 2830-2843
86. Collins S.J., Gallo R.C., and Gallagher R.E. Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature 270 (1977) 347-349
87. Borenfreund E., and Puerner J.A. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol. Lett. 24 (1985) 119-124
88. Molecular Operating Environment (MOE). Developed and distributed by Chemical Computing Group. http://wwwchemcompcom.
89. Babel3. Developed and distributed by Openeye Scientific Software. www.eyesopen.com.